CTXR stock forecast benefits from strong sector tailwinds. With FDA approvals ticking higher this year, micro-cap biotech plays like CTXR tend to see speculative inflows, though volatility risk remains elevated in pre-commercial phases. Still, Wall Street expects sales to fall 8% for the full year to $520 million before rebounding in 2025. Analysts forecast a 7% increase in sales to $555 million. Profits are expected to plunge to 3 cents per share from 21 cents before bouncing higher to 11 cents per share the following year. View our latest analysis for Citius Pharmaceuticals Technical chart watchers highlight that CTXR’s MACD line crossed above the signal line, supporting the CTXR stock forecast for continued short-term gains. This classical indicator aligns with recent upticks in sector ETF inflows.
Return this item within 90 days of purchase.
Get an immediate answer with AI
AI-generated from the text of manufacturer documentation. To verify or get additional information, please contact The Home Depot customer service.